Target Name: CELF2
NCBI ID: G10659
Review Report on CELF2 Target / Biomarker Content of Review Report on CELF2 Target / Biomarker
CELF2
Other Name(s): hNAPOR | OTTHUMP00000019077 | CELF2_HUMAN | KDM2B/CELF2 fusion | bruno-like protein 3 | neuroblastoma apoptosis-related RNA-binding protein | OTTHUMP00000019078 | Neuroblastoma apoptosis-related RNA-binding protein | CUGBP2 | CUGBP Elav-like family member 2 | NAPOR-2 | DEE97 | CUG-BP2 | ETR3 | NAPOR | CUGBP Elav-like family member 2 (isoform 2) | ELAV-type RNA-binding protein 3 | BRUNOL3 | OTTHUMP00000019076 | CUGBP Elav-like family member 2, transcript variant 3 | CUGBP Elav-like family member 2, transcript variant 5 | ETR-3 | CELF2 variant 2 | CELF2 variant 3 | Bruno-like protein 3 | CELF-2 | CUG triplet repeat, RNA binding protein 2 | CUGBP Elav-like family member 2 (isoform 5) | CELF2 variant 5 | CUGBP Elav-like family member 2 (isoform 3) | CUG triplet repeat RNA-binding protein 2 | CUGBP Elav-like family member 2, transcript variant 2 | CUG-BP- and ETR-3-like factor 2 | RNA-binding protein BRUNOL-3

CELF2: A protein involved in cytoplasmic environment and cell division

CELF2, short for cytoplasmic index filament 2, is a protein that is expressed in most tissues of the body. It is a member of the cytoplasmic index (CIP) family, which is a group of proteins that play an important role in the cytoplasm, the fluid that surrounds cells.

CELF2 is a 24-kDa protein that is expressed in most tissues of the body, including the brain, heart, liver, and muscle. It is primarily localized to the cytoplasm of cells, where it is involved in the formation and maintenance of the cytoplasmic environment.

One of the unique features of CELF2 is its ability to interact with other proteins in the cytoplasm. It has been shown to interact with several different proteins, including the protein known as p16INK4a. This protein is a well-known target for drugs that are used to inhibit the activity of cancer cells.

Another interesting property of CELF2 is its role in the regulation of cell division. It has been shown to play a role in the regulation of mitosis, the process by which a cell divides.

CELF2 has also been shown to be involved in the regulation of cell death. It has been shown to play a role in the regulation of apoptosis, the process by which a cell undergoes programmed cell death.

CELF2 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of the immune response, specifically in the regulation of T cell development.

CELF2 is also involved in the regulation of the blood-brain barrier. It has been shown to play a role in the regulation of the movement of materials into and out of cells, including the movement of neurotransmitters across the blood-brain barrier.

CELF2 has also been shown to be involved in the regulation of the nervous system. It has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for the function of the nervous system.

CELF2 is also involved in the regulation of the endoplasmic reticulum. It has been shown to play a role in the regulation of protein synthesis and the transport of proteins into and out of the endoplasmic reticulum.

In conclusion, CELF2 is a protein that is expressed in most tissues of the body and is involved in a wide range of cellular processes. Its unique ability to interact with other proteins in the cytoplasm and its role in the regulation of cell division, apoptosis, inflammation, blood-brain barrier, and nervous system make it an attractive drug target and a potential biomarker. Further studies are needed to fully understand the role of CELF2 in cellular processes and its potential as a drug target.

Protein Name: CUGBP Elav-like Family Member 2

Functions: RNA-binding protein implicated in the regulation of several post-transcriptional events. Involved in pre-mRNA alternative splicing, mRNA translation and stability. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of TNNT2 in embryonic, but not adult, skeletal muscle. Activates TNNT2 exon 5 inclusion by antagonizing the repressive effect of PTB. Acts as both an activator and repressor of a pair of coregulated exons: promotes inclusion of the smooth muscle (SM) exon but exclusion of the non-muscle (NM) exon in actinin pre-mRNAs. Promotes inclusion of exonS 21 and exclusion of exon 5 of the NMDA receptor R1 pre-mRNA. Involved in the apoB RNA editing activity. Increases COX2 mRNA stability and inhibits COX2 mRNA translation in epithelial cells after radiation injury (By similarity). Modulates the cellular apoptosis program by regulating COX2-mediated prostaglandin E2 (PGE2) expression (By similarity). Binds to (CUG)n triplet repeats in the 3'-UTR of transcripts such as DMPK. Binds to the muscle-specific splicing enhancer (MSE) intronic sites flanking the TNNT2 alternative exon 5. Binds preferentially to UG-rich sequences, in particular UG repeat and UGUU motifs. Binds to apoB mRNA, specifically to AU-rich sequences located immediatly upstream of the edited cytidine. Binds AU-rich sequences in the 3'-UTR of COX2 mRNA (By similarity). Binds to an intronic RNA element responsible for the silencing of exon 21 splicing (By similarity). Binds to (CUG)n repeats (By similarity). May be a specific regulator of miRNA biogenesis. Binds to primary microRNA pri-MIR140 and, with CELF1, negatively regulates the processing to mature miRNA (PubMed:28431233)

The "CELF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CELF2-AS1 | CELF2-AS2 | CELF3 | CELF4 | CELF5 | CELF6 | CELP | CELSR1 | CELSR2 | CELSR3 | CEMIP | CEMIP2 | CEMP1 | CENATAC | CEND1 | CENP-A-nucleosome distal (CAD) centromere complex | CENPA | CENPA-CAD (nucleosome distal) complex | CENPA-NAC (nucleosome-associated) complex | CENPB | CENPBD1P | CENPBD2P | CENPC | CENPCP1 | CENPE | CENPF | CENPH | CENPI | CENPIP1 | CENPJ | CENPK | CENPL | CENPM | CENPN | CENPO | CENPP | CENPQ | CENPS | CENPS-CORT | CENPT | CENPU | CENPV | CENPVL1 | CENPW | CENPX | Centralspindlin complex | CEP104 | CEP112 | CEP120 | CEP126 | CEP128 | CEP131 | CEP135 | CEP152 | CEP162 | CEP164 | CEP170 | CEP170B | CEP170P1 | CEP19 | CEP192 | CEP20 | CEP250 | CEP290 | CEP295 | CEP295NL | CEP350 | CEP350-FGFR1OP-MAPRE1 complex | CEP41 | CEP43 | CEP44 | CEP55 | CEP57 | CEP57L1 | CEP63 | CEP68 | CEP70 | CEP72 | CEP72-DT | CEP76 | CEP78 | CEP83 | CEP83-DT | CEP85 | CEP85L | CEP89 | CEP95 | CEP97 | CEPT1 | CER1 | Ceramidase | Ceramide synthase | CERCAM | CERK | CERKL | CERNA2 | CERS1 | CERS2 | CERS3 | CERS3-AS1